Advice

In the absence of a submission from the holder of the marketing authorisation:

eculizumab (Soliris ®) is not recommended for use within NHSScotland.

Indication under review: Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice361KB (PDF)

Download

Medicine details

Medicine name:
eculizumab (Soliris)
SMC ID:
SMC2236
Indication:

Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. 

Pharmaceutical company
Alexion Pharma UK Ltd
BNF chapter
Submission type
Non submission
Status
Not recommended
Date advice published:
07 October 2019